Related Experiment Video
Updated: Jul 11, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Advances in long-term stroke prevention with antiplatelet therapy
1Division of Neurology, Yale University School of Medicine, and Veterans Affairs Medical Center, New Haven, CT 06520-8018, USA.
Antiplatelet therapies like aspirin, clopidogrel, and dipyridamole are vital for preventing secondary ischemic strokes. Newer treatments offer effective options, but higher aspirin doses increase adverse events without improving efficacy.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Stroke is a primary cause of death and disability globally.
- Antiplatelet therapy is a proven strategy for secondary ischemic stroke prevention.
Purpose of the Study:
- To review the efficacy of various antiplatelet agents in secondary ischemic stroke prevention.
- To highlight recent advancements in antiplatelet therapy for stroke patients.
Main Methods:
- Review of randomized controlled trials evaluating antiplatelet agents.
- Comparative analysis of aspirin, clopidogrel, ticlopidine, and dipyridamole efficacy and safety.
Main Results:
- Aspirin is effective, but higher doses offer no additional benefit and increase adverse events.
- Clopidogrel and ticlopidine demonstrate superior efficacy over aspirin in preventing recurrent ischemic events.
- Combination therapy (aspirin with sustained-release dipyridamole) shows enhanced effectiveness, particularly in reducing nonfatal strokes.
Conclusions:
- Current evidence supports the use of specific antiplatelet agents and combinations for secondary stroke prevention.
- Newer antiplatelet treatment options provide effective strategies to reduce stroke recurrence and associated mortality.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis III: Management
Venous Thrombosis III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...